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Abstract. In the context of the hypothesis that the 
mitochondria represent primary sites of steroid hormone 
action we have evaluated the possible role of two nucleotide 
sequences partially homologous to Glucocorticoid 
Responsive Elements (GREs) present in the cytochrome 
oxidase subunit I gene of mouse and human mitochondrial 
DNA, as binding sites for mitochondrial and nuclear 
regulatory protein(s). Using a gel retardation assay, we 
examined whether proteins contained in mitochondrial and 
nuclear extracts from untreated and dexamethasone treated 
MCF7 and LATK' cell lines bind to these oligonucleotides. 
Both the mitochondrial and nuclear extracts from these cell 
lines contain protein(s) that bind to the oligonucleotides, as 
well as to the GRE of the human metallothionein II A 
promoter, binding which was considerably enhanced when 
the extracts were derived from cells previously treated with 
dexamethasone. 
Introduction 
Steroid hormones regulate metabolic and developmental 
processes by interacting with receptor proteins, representing 
ligand-dependent nuclear transcription factors, subsequent 
binding of the hormone-receptor complex to enhancer 
elements, called hormone responsive elements (HRE) and 
modulation of gene expression (1-3). The presence of HREs in 
genes implies potential hormone responsiveness of these 
genes. 
We have postulated, based, among other findings (4-7), 
on the demonstration of the presence in human and rodent 
mitochondrial DNA of nucleotide sequences partially 
homologous to HREs, a direct action of steroid hormones on 
mitochondrial gene expression (8,9). The presence of 
Correspondence to: Professor CE. Sekeris, Institute of Biological 
Research and Biotechnology, National Hellenic Research 
Foundation, 48 Vas. Constantinou Avenue, Athens 116 35, Greece 
Key words: glucocorticoid receptor, mitochondrial DNA, 
glucocorticoid responsive element 
glucocorticoid receptor in mitochondrial extracts of liver in 
dexamethasone treated rats, has been demonstrated both by 
electron microscopy and Western blotting (10; Sekeris CE, 
Demonakos C, Markovic-Djordjevic R, Papalopoulou M, 
Spandidos DA, Tsawdaroglou Ν and Tsiriyotis C, unpublished 
results) providing further support to this hypothesis. 
In this paper we have evaluated, by a gel retardation 
assay, the role of two nucleotide sequences present in the 
cytochrome oxidase subunit I gene, showing partial 
homology to GREs, as binding sites for regulatory proteins 
present in mitochondrial and nuclear extracts from two cell 
lines, one human and one mouse, subjected or not, to 
inducing dose of dexamethasone. As is well established both 
cell lines possess glucocorticoid receptors (11,12) and thus 
are responsive to glucocorticoid treatment. 
To this aim we have synthesized oligonucleotides 
containing the two putative mitochondrial GREs, as well as an 
oligonucleotide containing a GRE from the human 
metallothionein IIA promoter, which, as known, is a binding 
site for glucocorticoid receptor (13), to be used as reference 
sequence. 
Materials and methods 
Two cell lines were used; MCF7 human breast cancer cells 
and LATK" mouse fibroblasts. After treatment of the cell 
lines with dexamethasone, nuclear and mitochondrial extracts 
were prepared from treated and untreated cells. The extracts 
have been used in binding experiments with double stranded 
32P-labelled synthetic oligonucleotides, containing the 
putative GREs from the mitochondrial DNA (mtCOIGREI 
and mtCOIGREII), or a known GRE from the human 
metallothionein IIA promoter (hMTIIAGRE). 
Cell culture. Both cell lines were grown in 75cm2 cell culture 
flasks in DMEM/F12 1:1 (Gibco) medium, containing 10% 
fetal calf serum (FCS), in a humidified atmosphere of 95% 
air and 5% C0 2 , at 37°C 48 hours prior to dexamethasone 
administration, the medium was replaced with DMEM/F12 
1:1, containing 10% FCS inactivated by dextran treated 
active charcoal. 24 hours after dexamethasone administration 
the cells were washed with PBS and collected by scraping. 
The same procedure was followed for control flasks without 
dexamethasone treatment. 
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Nuclear extract preparation. The cells were homogenized in 
2 ml hypotonic buffer (25 mM Tris HCl pH 7.5, 5 mM KCl, 
0.5 mM MgCU, 0.5 mM DTT. 0.5 mM PMSF). The nuclei 
were pelleted at 2500 rpm for 10 min at 4°C, then washed 3 
times with 2 ml isotonic buffer (25 mM Tris HCl pH 7.5, 5 
mM KCl, 0.5 mM MgCl2, 0.2 mM Surcose, 0.5 mM DTT, 1 
mM PMSF) and lysed with an extraction buffer (25 mM Tris 
HCl pH 7.5, 1 mM EDTA, 0.1% Triton, 0.5 mM DTT, 0.5 
mM PMSF). Nuclear debris was removed by centrifugation 
at 25000 rpm for 1 hour in a Beckman 80 Ti rotor at 4°C. The 
protein concentration of the supernatant was measured as 
described by Bradford (14). 
Mitochondrial extract preparation. The cells were lysed in 
homogenization buffer (10 mM Hepes, 250 mM surcose, 1 
mM EDTA, 0.002% NaN„ 100 μΜ PMSF) using a glass 
homogenizer. Mitochondria were purified by ultra-
centrifugation with a Beckman 80 Ti fixed angle rotor, at 
35,000 rpm, for 1 h at 4°C, using a Percoli (Pharmacia) 
gradient containing 0.15 M surcose. The purified 
mitochondria were broken in a salt buffer (20 mM Tris HCl 
pH 7.5, 0.6M NaCl, 10 mM ß-mercaptoethanol, 10% 
glycerol, 100 μΜ PMSF) and the debris was removed by 
ultra-centrifugation in a 80 Ti Beckman rotor at 40,000 rpm 
at 4°C for 90 min. Protein estimation was carried out as for 
nuclear extracts. 
Chemical synthesis of oligonucleotides. The following six 
single stranded oligonucleotides (27 mers) [1-6] were 
synthesized on an Applied Biosystems 381A DNA 
synthesizer: 
mtCOIGRE I 6018-6033 
5'-AGCTTACCAGCATCTGTTCTGAATTCA-3' [1] 
3'-A T G G T C G T A G A C A A G A C T T A A G T T C G A-5' [2] 
GRE Bam HI 
mtCOIGREII 6455-6469 
5 ' A G C T T T T T C C A C T A T G T T C T G A A T T C A-3' [3] 
3'-A AAAGGTGATACAAGACTTAAGTTCG A-5' [4] 
GRE Bam HI 
hMT IIA GRE 
5 ' - A G C T T G G T A C A C T G T G T C C T G A A T T C A-3' [5] 
3 '-ACCATGTGACACAGGACTTAAGTTCG A-5' [6] 
GRE Bam HI 
The first fl] oligonucleotide is complementary to the second 
[2], the third [3] to the fourth [4] and the fifth [5] to the sixth 
[6]. When annealed, they produce double-stranded GREs. 
They also contain BamHI restriction sites as indicated and 
Hindlll ends. The number shows their position in the mt 
genome (in the cytochrome oxidase I gene). The hMT IIA 
GRE oligonucleotide contains the GRE from the human 
metallothionein promoter, which is responsive to 
glucocorticoids. The positions of mtCOIGREI and 
mtCOIGREII in the mitochondrial genome are indicated in 
Fig. 1 (8,15). 
After synthesis, the oligonucleotides were removed from 
the column by elution with 3 χ 1 ml of ammonia, incubated 
at 55°C overnight for deprotection and further purified 
through an oligonucleotide purification cartridge (OPC) from 
Applied Biosystems. Annealing of complementary couples 
was carried out by incubation of 0.05 M in TE each strand at 
90°C and slow cooling to less than 30°C. To confirm the 
formation of double stranded oligonucleotides, samples were 
run on an 8% Polyacrylamide gel parallel to the single 
stranded oligonucleotides. Oligonucleotides containing the 
NF1 or Spi binding sequences were a gift from Dr A. 
Pintzas. 
Oligonucleotide labelling. The three double stranded 
oligonucleotides were end-labelled with γ32Ρ-ΑΤΡ using T4 
polynucleotide kinase (Boehringer). The reaction was carried 
out for 30 min at 37°C, then at 70°C for 5 min, at 37°C for 10 
min, at room temperature for 5 min and on ice for 5 min. 
Gel retardation assays. DNA binding reactions were carried 
out as follows: 2,000 cpm Y12P-oligonucleotide were mixed 
with nuclear or mitochondrial proteins (20 μg) in binding 
buffer (50 mM Hepes pH 8.0, 500 mM NaCl, 0.5 mM PMSF, 
0.5 mg/ml BSA, 20 % glycerol, 1 mM EDTA) plus 1 mM 
DTT and 150 mg/ml poly (dl-dC). The reaction mixture was 
incubated for 30 min at 4°C. For the competition 
experiments, an incubation of 20 min at 4°C, in the presence 
of the competitor, was carried out, prior to the addition of the 
radioactive probe. Samples were electrophoresed on 5% 
Polyacrylamide gels, then dried and exposed to X-ray film 
(RX Fuji) at -70°C. 
Results 
LATK" cells were cultured in medium containing 10% 
charcoal inactivated serum for 48 hours and then either 
treated with 1 μΜ dexamethasone for 24 h, or left untreated. 
From treated and untreated cells nuclear and mitochondrial 
extracts were prepared. All extracts were used in retardation 
assays involving the three synthetic oligonucleotides 
mentioned in Materials and methods, in order to investigate 
the presence of protein(s), among them possibly the 
glucocorticoid receptor, which bind to the oligonucleotides 
and whether this binding is influenced by glucocorticoid 
treatment. The same experiments were carried out with the 
MCF7 cell line. 
In the following two figures are presented the results of 
the gel retardation assays in the presence of mitochondrial 
(Fig. 2) and nuclear (Fig. 3) extracts, respectively, of LATK 
cells, not subjected to dexamethasone treatment (Fig. 2, lanes 
1, 6 and 11 and Fig. 3, lanes 2, 4, 6, 8, 10 and 12). Both 
extracts show the presence of protein(s) binding to all three 
oligonucleotides used. This binding is increased if the 
extracts are derived from cells previously treated with an 
inducing dose (1 μΜ) of dexamethasone (Fig. 2, lanes 2, 7 
and 12 and Fig. 3, lanes 3, 7 and 11). This increase of 
binding activity after hormonal induction is evident 
particularly in the mitochondrial extracts. 
It is apparent that the same retardation band is observed 
after interaction of the mitochondrial and nuclear extracts from 
LATK" cells, both with mtGREI, and mtGREII and with the 
hMTIIAGRE. We then performed competition experiments 
using as competitors mtCOIGREI, mtCOIGREII. hMTII ,GRE 




Figure 1. The mitochondrial genome of mammalian cells, indicating the 
position of GRE-like elements (mtCOIGREI and mtCOIGREII) (taken from 
references 8 and 14). 
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Figure 3. Electrophoretic mobility shift analysis using mtCOIGREI 
(mtGREI). mtCOIGREII (mtGREII) and hMTIIAGRE oligonucleotides and 
mitochondrial extracts from LATK cells not treated and treated with 1 μΜ 
dexamethasone. GR indicates the band resulting from protein binding to the 
probe. Binding to mtCOIGREI. lanes 2-5, to mtCOIGREII, lanes 6-9 and to 
hMTH.
s
GRE. lanes I 1-13. Non-treated cells, lanes 2. 4, 6. 8, 10 and 12, 
dexamethasone treated, lanes 3, 5. 7. 9, II and 13. Competition with 
mtCOIGREI. lanes 4 and 5, with mtCOIGREII, lanes 8 and 9 and with 
hMTII.GRE, lanes 12 and 13. 
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Figure 2. Electrophoretic mobility shift analysis using mtCOIGREI 
(mtGREI). mtCOIGREII (mtGREII) and hMTIIAGRE oligonucleotides and 
mitochondrial extracts from LATK cells not treated and treated with 1 μΜ 
dexamethasone. GR indicates the band resulting from protein binding to the 
probe. Binding to mtCOIGREI. lanes 1-5, to mtCOIGREII. lanes 6-10 and 
to hMTII A GRE. lanes 11-15. Non-treated cells, lanes 1. 6 and 11, 
dexamethasone treated, lanes 2, 3, 4 .5. 7. 8. 9. 12. 13, 14 and 15. 
Competition with mtCOIGREI (mtGREI). lanes 3. 8 and 13. with 
mtCOIGREII (mtGREII). lanes 4. 9 and 14. with hMTII
x
GRE. lanes 4, 9 
and 13 and with NF1. lanes 5. 10, 15. 
and NF1, the latter containing no sequences related to GREs. 
mtCOIGREI (Fig. 2, lanes 3 and 14), mtCOIGREII (Fig. 2, 
lane 8) and hMTIIAGRE (Fig. 2, lanes 4, 9 and 13) competed 
binding of mitochondrial proteins to mtCOIGREI, 
mtCOIGREII and hMTIIAGRE. On the other hand, NF1 
showed only partial competition with mtGREI (Fig 2. lane 5) 
and no competition with mtCOIGREII (Fig. 2, lane 10) and 
hMTIIAGREII (Fig. 2, lane 15). Similar competition 
experiments were carried out with nuclear extracts from 
LATK cells. All three oligonucleotide probes used 
(mtCOIGREI, mtCOIGREII and hMTIIAGRE) competed 
effectively (Fig. 3, lanes 4, 5, 8, 9, 12 and 13). Nuclear 
extracts from HeLa cells show binding to hMTIIAGRE, 
exhibiting the same electrophoretic mobility shift (Fig. 3, 
lane 1) as the extracts from LATK cells. 
Similar experiments to those as with LATK' cells were 
carried out using mitochondrial and nuclear extracts from 
MCF7 cells (Figs. 4, 5 and 6). As in the experiments with 
LATK cells we were able to detect the presence of proteins 
binding to mtCOIGREI (Fig. 4, lanes 1-5), mtCOIGREII 
(Fig. 4, lanes 6-10) and hMTIIAGRE (Fig. 4, lanes 11-15) in 
mitochondrial extracts from control and dexamethasone 
treated MCF7 cells. Binding to the three probes was 
significantly elevated in the mitochondrial extracts compared 
to dexamethasone treated cells (Fig. 4, compare lanes 1 and 
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Figure 4. Electrophoretic mobility shift analysis using mtCOIGREI 
(mtGREI). mtCOIGREII (mtGREII) and hMTIIAGRE oligonucleotides and 
mitochondrial extracts from MCF7 cells not treated and treated with 1 μΜ 
dexamethasone. Binding to mtGREI, lanes 1-5, to mtCOIGREII, lanes 6-10 
and to hMTIIAGRE lanes 11-15. Non-treated cells, lanes 1, 6 and 11, 
dexamethasone treated, lanes 2, 3, 4, 5, 7, 8, 9, 12, 13, 14 and 15. 
Competition with mtCOIGREI, lanes 3 and 14, with mtCOIGREII, lane 8 
with hMTII, GRE lanes 4, 9 and 13 and with NF1, lanes 5, 10 and 15. 
2, 6 and 7 and 11 and 12). Competition experiments showed 
that, whereas binding to mtCOIGREI was competed with 
mtCOIGREI or hMTIIAGRE (Fig. 4, lanes 3 and 4), binding 
to mtCOIGREII was competed by mtCOIGREII and 
hMTIIAGRE (Fig. 4, lanes 8 and 9) and binding to 
hMTIIAGRE was competed by hMTIIAGRE and mtCOIGREI 
(Fig. 4, lanes 13 and 14), NF1 did not compete with any of 
the radioactive probes (Fig. 4, lanes 5, 10 and 15). 
In a similar series of experiments using nuclear extracts 
from control (Fig. 5, lanes 1, 3 and 7) and dexamethasone 
treated (Fig. 5, lanes 2, 4, 5, 6, 8, 9, 10, 11) MCF7 cells, we 
were able to demonstrate that binding to mtGREI increased 
after dexamethasone treatment (Fig. 5, compare lanes 1 and 2). 
Both mtCOIGREI (Fig. 5, lanes 3, 4, 5 and 6) and 
hMTIIAGRE (Fig. 5, lanes 10 and 11) competed with the 
mtCOIGREI probe. On the other hand, Spi (Fig. 5, lanes 7, 8 
and 9), which shows no similarity to GREs, did not compete 
even at high ratio of competitor to radioactive probe (300 to 1 ). 
We include in Fig. 5 the results of binding of mitochondrial 
extracts from untreated MCF7 cells (Fig. 5, lane 12) and 
from nuclear extracts of untreated HeLa cells (Fig. 5, lane 
13) to mtCOIGREI, so as to show that the formed complex 
shows the same mobility as the DNA/protein complex 
formed by the nuclear extracts from MCF7 cells. 
The same experiments as above were repeated with 
nuclear extracts from MCF7 cells using as probe the 
hMTIIAGRE (Fig. 6). Nuclear extracts from dexamethasome 
treated cells showed increased binding to the hMTIIAGRE 
FREE 
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Figure 5. Electrophoretic mobility shift analysis using mtCOIGREI 
(mtGREI), mtCOIGREII (mtGREII) and hMTIIAGRE oligonucleotides and 
mitochondrial extracts from MCF7 cells not treated and treated with Ι μΜ 
dexamethasone. Binding to mtCOIGREI probe, lanes 1-11. Non-treated 
cells, lanes 1, 3 and 7, dexamethasone treated, lanes 2, 4, 5, 6, 8, 9, 10 and 
11. Non-competed, lanes 1 and 2, competition with mtCOIGREI (with the 
indicated ratio of radioactive probe to competitor as indicated), lanes 3, 4, 5 
and 6, with Spi, lanes 7, 8 and 9 and with hMTIIAGRE, lanes 10 and 11. 
Lane 12 represents binding of mitochondrial extracts from non-treated 
MCF7 cells to mtCOIGREII probe, in the absence of competition. Lane 13 
represents binding of nuclear extracts from HeLa cells to mtGREII probe in 
the absence of a competitor. 
probe (Fig. 6, compare lanes 1 and 2). Furthermore, the 
hMTIIAGRE (Fig. 6, lanes 3 to 6), competed with the 
radioactive hMTIIAGRE probe, whereas Spi (Fig. 6, lanes 7 
to 9), even at high ratio of competitor to radioactive 
hMTIIAGRE probe (300/1), did not compete. In Fig. 6 we 
include results of binding to hMTIIAGRE of extracts from 
MCF7 untreated cells (lane 10), of extracts from nuclei of 
untreated HeLa cells (lane 11 ) and of extracts from untreated 
LATK' cells (lane 13). We also show the mobility shift of the 
complex formed by the interaction of the mtCOIGREI probe 
with MCF7 nuclear extracts (lane 12). It is evident that the 
DNA/protein complexes formed have the same electrophoretic 
mobility (compare lanes 1,2, 10, 11, 12 and 13). 
Discussion 
Steroid hormones are known effectors of mitochondrial 
functions (5-7,16-21). It is generally assumed that the 
steroidal effects on mitochondria are secondary, due to a 
primary action on nuclear gene expression, by way of the 
now well understood mechanism of hormone-receptor 
complex binding to the appropriate Hormone Responsive 
Elements (HREs). The rapid entrance of glucocorticoids in 
liver mitochondria (4,5), the evoked stimulation of 
mitochondrial transcription by glucocorticoids (5.6.23) and 
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Figure 6. Electrophoretic mobility shift analysis using hMTIIAGRE 
oligonucleotide and nuclear extracts from MCF7 cells not treated and 
treated with Ι μΜ dexamethasone. Binding to hMTIIAGRE probe, lanes 1-9. 
Non-treated cells, lanes 1. 3 and 7. dexamethasone treated, lanes 2, 4, 5, 6, 8 
and 9. Non-competed, lanes 1 and 2, competed with hMTIIAGRE, lanes 3, 4. 
5 and 6 and with Spi. lanes 7. 8 and 9. Lane 10 represents binding of 
mitochondrial extracts of non-treated MCF7 cells to hMTHAGRE in the 
absence of a competitor. Lane 11 represents binding of nuclear extracts of 
dexamethasone treated HeLa cells to hMTIIAGRE in the absence of a 
competitor. Lane 12 represents binding of nuclear extracts of 
dexamethasone treated MCF7 cells to mtCOIGREI in the absence of a 
competitor and lane 13 represents binding of nuclear extracts of 
dexamethasone treated LATK" cells to hMTIIAGRE in the absence of a 
competitor. 
other hormones (23-27) and the presence in the mitochondrial 
genome of nucleotide sequences with partial homology to 
HREs (8,9), led to the formulation of the hypothesis of a 
direct action of steroid hormones on mitochondrial gene 
expression (8,9). The demonstration that the glucocorticoid 
receptor rapidly translocates from the cytoplasm into liver 
mitochondria after glucocorticoid administration to rats (10; 
Sekeris et al in preparation) is further support for the 
hypothesis of a direct mitochondrial effect of steroid 
hormones. Furthermore, various reports strongly suggest that 
these hormones are involved in the regulation of transcription 
of mtDNA (5,6.24-27). The mechanism through which 
glucocorticoids interact with mitochondria is not yet known. 
As far as the nucleus is concerned, steroids exert many of 
their important actions by activating the corresponding 
receptor, which, by binding to the appropriate HRE, 
modulates gene expression (5,7). Other steroid effects could 
be mediated by non-DNA binding mechanisms, involving 
protein-protein interaction (28,29). Either mechanisms could 
be applicable in the case of mitochondria, or another novel 
and distinct mechanism could exist. Our results favour the 
direct interaction of the receptor with mitochondrial DNA. 
We have shown that two of the putative mtCOIGREs 
existing in the cytochrome oxidase subunit I gene interact 
with protein(s), which also bind to the metallothionein IIA 
promoter GRE, used as a standard glucocorticoid binding 
nucleotide sequence. These protein(s) are present in both 
nuclear and mitochondrial extracts, as both extracts give the 
same band in the gel retardation assays. Moreover, after 
dexamethasone treatment, binding of the protein(s) to all 
three synthetic oligonucleotides is considerably enhanced. 
We interpret this increase in binding as a result of a 
dexamethasone induced translocation of the glucocorticoid 
receptor of MCF7 and LATK' cells from the cytoplasm to the 
mitochondria and nuclei. The similarity of the bands formed 
in the gel retardation assays after interaction of nuclear 
extracts with the hMTIIAGRE and those formed in the assays 
using nuclear and mitochondrial extracts with mtGREI and 
mtGREII strongly suggest that the glucocorticoid receptor 
represents a major protein in the extracts interacting with the 
oligonucleotide probes. The binding is quite specific, as the 
formed DNA/protein bands disappear when the 
oligonucleotides compete with themselves (or with the 
metallothionein GRE), but not in competition assays with 
Spi and NF1 oligonucleotides, which do not contain GREs. 
Similar results in gel retardation assays as those presented in 
this paper have been obtained using cloned mitochondrial 
DNA fragments, containing the putative GREs and purified 
glucocorticoid receptor or rat liver mitochondrial extracts 
demonstrating binding of GR to the putative mitochondrial 
GREs (Demonakos C, Tsawdaroglou Ν and Sekeris CE, 
unpublished results). 
The role that these potential mtGREs may play in the 
regulation of mitochondrial gene expression is under 
consideration. The circular mtDNA shows differences both 
in structure and expression as compared to the nuclear 
genome. There are no introns in the mitochondrial genome 
and the genes are transcribed in a way reminiscent of 
bacterial opérons. The two putative mtCOIGREs do not 
reside in the D-loop area, which contains the promoters and 
is not transcribed, but in various open reading frames. Do 
these mtCOIGREs play a role in the activation or 
enhancement of the transcription, or is their function 
different from their nuclear counterparts, i.e. could they be 
involved in the elongation or stability of the nascent 
transcripts? These questions are currently being explored, 
using among others, CAT-transfection studies, in which 
competent cells are transfected with constructs made up of 
the CAT gene linked to the putative mitochondrial GREs. 
The demonstration that mitochondrial and nuclear 
proteins, probably among them the glucocorticoid receptor, 
bind to mitochondrial DNA sequences with strong homology 
to GREs, strongly suggests that the known glucocorticoid 
effects on both nuclear and mitochondrial metabolism are 
coordinated by the presence in the mitochondrial and nuclear 
genome of common regulatory elements. 
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